CN112204027A - Erk 抑制剂及其应用 - Google Patents

Erk 抑制剂及其应用 Download PDF

Info

Publication number
CN112204027A
CN112204027A CN201980031575.0A CN201980031575A CN112204027A CN 112204027 A CN112204027 A CN 112204027A CN 201980031575 A CN201980031575 A CN 201980031575A CN 112204027 A CN112204027 A CN 112204027A
Authority
CN
China
Prior art keywords
pyridin
chloro
hydroxymethyl
pyrazin
methoxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980031575.0A
Other languages
English (en)
Inventor
吴颢
唐晓婧
谷伟
吴文茂
沈益飞
杨晓峰
王维
湛波
赵新涛
冯东杰
陈忠研
柯永新
兰宏
王家炳
丁列明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of CN112204027A publication Critical patent/CN112204027A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明涉及一种作为胞外信号调节激酶(ERK)抑制剂的化合物(如式(Ⅰ)所示)及其药物组合物、制备方法，以及其在治疗ERK介导的疾病中的用途。本发明的化合物通过参与调节细胞增殖、凋亡、迁移、新生血管生成等多个过程而发挥作用。

Description

PCT国内申请，说明书已公开。

Claims (41)

  1. PCT国内申请，权利要求书已公开。
CN201980031575.0A 2018-06-08 2019-06-06 Erk 抑制剂及其应用 Pending CN112204027A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018090384 2018-06-08
CNPCT/CN2018/090384 2018-06-08
CNPCT/CN2018/120976 2018-12-13
CN2018120976 2018-12-13
PCT/CN2019/090220 WO2019233456A1 (zh) 2018-06-08 2019-06-06 Erk抑制剂及其应用

Publications (1)

Publication Number Publication Date
CN112204027A true CN112204027A (zh) 2021-01-08

Family

ID=68770076

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980031575.0A Pending CN112204027A (zh) 2018-06-08 2019-06-06 Erk 抑制剂及其应用

Country Status (3)

Country Link
CN (1) CN112204027A (zh)
TW (1) TW202016113A (zh)
WO (1) WO2019233456A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022268065A1 (en) * 2021-06-22 2022-12-29 Fochon Biosciences, Ltd. Compounds as erk inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202214563A (zh) * 2020-06-11 2022-04-16 大陸商貝達藥業股份有限公司 雙環化合物、包含其的藥物組合物及其應用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106164076A (zh) * 2014-03-27 2016-11-23 詹森药业有限公司 作为ROS1抑制剂的被取代的4，5，6，7‑四氢‑吡唑并[1，5‑a]吡嗪衍生物和5，6，7，8‑四氢‑4H‑吡唑并[1，5‑a][1，4]二氮杂环庚三烯衍生物
WO2017080980A1 (en) * 2015-11-09 2017-05-18 Astrazeneca Ab Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106164076A (zh) * 2014-03-27 2016-11-23 詹森药业有限公司 作为ROS1抑制剂的被取代的4，5，6，7‑四氢‑吡唑并[1，5‑a]吡嗪衍生物和5，6，7，8‑四氢‑4H‑吡唑并[1，5‑a][1，4]二氮杂环庚三烯衍生物
WO2017080980A1 (en) * 2015-11-09 2017-05-18 Astrazeneca Ab Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG, XIAOXIAO ET AL.: "Phosphomolybdate assembly as a low-cost catalyst for the reduction of toxic Cr(VI) in aqueous solution" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022268065A1 (en) * 2021-06-22 2022-12-29 Fochon Biosciences, Ltd. Compounds as erk inhibitors

Also Published As

Publication number Publication date
TW202016113A (zh) 2020-05-01
WO2019233456A1 (zh) 2019-12-12

Similar Documents

Publication Publication Date Title
CN110627796B (zh) 含氮杂环类衍生物及其在医药上的应用
EP2651899B1 (en) Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
CN106103416B (zh) 作为trpm8拮抗剂的氮杂螺衍生物
CN105980387B (zh) 丝氨酸/苏氨酸激酶抑制剂
TW202214605A (zh) 免疫調節劑、組合物及其方法
TWI697490B (zh) 用於作為shp2抑制劑之新穎雜環衍生物
WO2018220149A1 (en) Compounds
TWI748142B (zh) 抗腫瘤劑
AU2021265578B2 (en) Azalactam compounds as HPK1 inhibitors
AU2016234209B2 (en) Fused bicyclic heteroaryl derivatives having activity as PHD inhibitors
TW202229300A (zh) 囊腫纖維化跨膜傳導調節蛋白之調節劑
CN112204024B (zh) Erk抑制剂及其应用
CA2993809C (en) Compounds and pharmaceutical composition associated with ubiquitination-proteasome system
CN112204027A (zh) Erk 抑制剂及其应用
AU2018252099B2 (en) Fluorine-substituted indazole compounds and uses thereof
CN116940573A (zh) 三环类化合物及其用途
AU2018276441B2 (en) Compounds
WO2022037694A1 (zh) 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
TW202132313A (zh) 咪唑烷酮類化合物、包含其的醫藥組合物及其應用
WO2023279986A1 (zh) 六元芳基或杂芳基酰胺类化合物及其组合物和用途
WO2024067714A1 (zh) 具有抗kras突变肿瘤活性的化合物
CN117715898A (zh) 六元芳基或杂芳基酰胺类化合物及其组合物和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210108